Pulmonary patients

Pulmonary Safety in

Pulmonary Safety pr

Not known pulmonary hypertension.

Pulmonary complications

Epistaxis Pulmonary haemorrhage

Flushing Pulmonary embolism

Pulmonary haemorrhage Uncommon

Pulmonary artery hypertension

Pulmonary eosinophilia

Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.

Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.

Rehabilitation

hypertension).

5 Pulmonary veno occlusive disease

23 Pulmonary veno occlusive disease

Very rare cough, pulmonary hypertension

Cardiac disorders Common congestive heart failure cardiac dysfunction, pericardial effusion, arrhythmia (including tachycardia), palpitations Uncommon myocardial infarction, pericarditis, ventricular arrhythmia (including ventricular tachycardia), angina pectoris, cardiomegaly Rare cor pulmonale, myocarditis, acute coronary syndrome

Embolism pulmonary, oedema, oedema peripheral

Skin and subcutaneous tissue disorders Very common

Deep venous thrombosis and pulmonary embolism

medical training?

vocational training?

Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

(b) Rehabilitation

TREATMENT AND REHABILITATION

Treatment and rehabilitation

Rehabilitation allowances

Rehabilitation allowance

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience (see section 4.4).

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience (see section 4.4).

However, since a significant percentage of these patients were

However, since a significant percentage of these patients were

Interstitial lung disease (including pneumonitis and pulmonary fibrosis)

Acute diffuse infiltrative pulmonary and pericardial disease.

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience.

Pulmonary events Severe pulmonary events have been reported rarely with the use of Herceptin in the post marketing setting (see 4.8).

Gastrointestinal disorders

Now he could put it to use.

Rehabilitation, Physiotherapy, and Spa Care

Treatment and rehabilitation

Pulmonary changes As with other alpha interferons, pulmonary symptoms, including dyspnoea, pulmonary infiltrates, pneumonia, and pneumonitis have been reported during therapy with Pegasys.

Article 26 Habilitation and rehabilitation

Rehabilitation Government policies Maintenance by synthetic alternatives

Treatment, including rehabilitation and remedial therapy.